Ascendis Pharma A/S (ADR) (OQ:ASND)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

May 14, 2024 02:31 pm ET

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food and Drug Administration (FDA) notified the Company that information submitted in response to the FDA’s ongoing review of the New Drug Application (NDA) for TransCon PTH...

May 13, 2024 08:30 am ET

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

Ascendis Pharma A/S (Nasdaq: ASND) today announced 2-year results from a post-hoc analysis of the Company’s Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function in adults with chronic hypoparathyroidism...

May 09, 2024 08:30 am ET

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024

Ascendis Pharma A/S (Nasdaq: ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at the European Congress of...

May 02, 2024 04:01 pm ET

Ascendis Pharma Reports First Quarter 2024 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2024, and provided a business update. “With SKYTROFA revenue more than doubling in the U.S. compared to the first quarter of 2023, and our...

Apr 25, 2024 04:46 pm ET

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2024 financial results and provide a business update on Thursday, May 2, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a...

Apr 24, 2024 08:30 am ET

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH® (palopegteriparatide; developed as TransCon™ PTH) in Great...

Mar 04, 2024 08:30 am ET

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 at 2:00 p.m. ET in Miami, Florida. A live webcast...

Feb 07, 2024 04:01 pm ET

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update. “In 2023, we streamlined Ascendis, including our structure, processes, and operating...

Feb 07, 2024 08:30 am ET

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Details: EventOppenheimer 34th Annual Healthcare Life Sciences...

Jan 31, 2024 04:15 pm ET

Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024

Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a...

Jan 31, 2024 04:01 pm ET

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now...

Jan 29, 2024 08:30 am ET

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an...

Jan 08, 2024 08:20 am ET

Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries

Vector Pharma FZCO (Vector) today announced that it has entered into an exclusive distribution agreement with Danish company Ascendis Pharma A/S (Nasdaq: ASND) to commercialize both Skytrofa™ and Yorvipath™ in the Gulf Cooperation Council (GCC)...

Jan 07, 2024 05:45 pm ET

Ascendis Pharma Introduces Vision 2030

Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual...

Jan 07, 2024 01:00 pm ET

Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries

Agreement between Ascendis Pharma A/S and ST is for the exclusive distribution and commercialisation of three Ascendis Pharma endocrinology therapiesTwo of the therapies are already internationally approved, the third is in development following successful Phase 2 dataST's exclusive distribution agreement covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand and VietnamSINGAPORE, Jan. 7, 2024 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has added three new endocrinology therapies to its specialist portfolio, following an excl

Dec 28, 2023 04:15 pm ET

Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice President & Chief Financial Officer, and Kennett Sprogøe, Ph.D., Executive Vice President, Head of Research &...

Dec 20, 2023 08:30 am ET

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week

Ascendis Pharma A/S (Nasdaq: ASND) today announced new analyses from the blinded and ongoing open-label extension (OLE) portions of ACcomplisH, the Company’s Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial of TransCon...

Dec 19, 2023 08:30 am ET

TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S (Nasdaq: ASND) today announced positive topline results from foresiGHt, its Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial to compare the efficacy and safety of...

Dec 11, 2023 08:30 am ET

FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adult...

Nov 29, 2023 04:30 am ET

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for...

Nov 20, 2023 08:00 am ET

Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for YORVIPATH® (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic...

Nov 15, 2023 08:00 am ET

Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA

Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adults with hypoparathyroidism to the U.S. Food & Drug Administration (FDA). The...

Nov 07, 2023 04:01 pm ET

Ascendis Pharma Reports Third Quarter 2023 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended September 30, 2023 and provided business updates. “This quarter marks an important milestone for Ascendis on our path to become a leading, sustainable...

Oct 31, 2023 08:30 am ET

Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission

Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the close of the U.S. financial markets. In addition, Ascendis Pharma announced...

Oct 26, 2023 08:30 am ET

Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

Ascendis Pharma A/S (Nasdaq: ASND) reported updated and new data from its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ in a poster presentation at ESMO 2023, the annual meeting of the European Society of Medical Oncology held in Madrid,...

Oct 16, 2023 04:01 pm ET

Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023

Ascendis Pharma A/S (Nasdaq: ASND) shared 52-week data from the open-label extension period of its ongoing Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) showing that adults with chronic hypoparathyroidism, whose bones tend to be...

Oct 02, 2023 08:00 am ET

Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting

Ascendis Pharma A/S (Nasdaq: ASND) presented a poster with results of a sub-analysis of its Phase 3 PaTHway clinical trial data during the recent American Thyroid Association (ATA) annual meeting, showing that 81% of adults with chronic...

Sep 23, 2023 07:00 am ET

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S (Nasdaq: ASND) today announced results from enliGHten, the Company’s open-label extension trial evaluating the long-term safety and efficacy of TransCon hGH as a once-weekly treatment for children and adolescents with growth...

Sep 15, 2023 08:00 am ET

Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA® (lonapegsomatropin), its growth hormone approved in the European Union for the once-weekly treatment of children and adolescents ages 3 to 18 years with growth...

Sep 14, 2023 12:22 pm ET

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended the approval of TransCon PTH (palopegteriparatide) as a...

Sep 05, 2023 04:15 pm ET

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa revenue. “This...

Sep 05, 2023 04:03 pm ET

Ascendis Pharma Reports Second Quarter 2023 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2023 and provided business updates. “We have built a fully integrated Endocrinology Rare Disease franchise with a growing commercial reach...

Sep 05, 2023 04:01 pm ET

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue. “This...

Sep 05, 2023 04:01 pm ET

New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism

- Approximately 50% of Phase 3 PaTHway Trial patients with eGFR 60 mL/min with TransCon PTH therapy. Number of Responders*Number of Responders* eGFR < 60(n, %)(n, %) at Baseline (n)Week 26Week 52TransCon PTH / TransCon...

Aug 24, 2023 08:30 am ET

Ascendis Pharma A/S Announces Three Upcoming Investor Presentations

Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in three upcoming investor conferences. Details:...

Aug 23, 2023 04:48 pm ET

Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

TSX: ASNDwww.ascendantresources.com

Aug 15, 2023 08:30 am ET

Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023

Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday, September 5, 2023, after the close of the U.S. financial markets. Ascendis Pharma will also host a...

Jun 30, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ascendis Pharma A/S (NASDAQ: ASND), Alvotech SA (NASDAQ: ALVO), Shift4 Payments, Inc. (NYSE: FOUR), and Waldencast Plc...

Jun 25, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zai Lab Limited (Zai Lab Limited), Hayward Holdings, Inc. (NYSE: HAYW), Ascendis Pharma A/S (NASDAQ: ASND), and Alvotech SA...

Jun 19, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against C3.ai, Inc. (NYSE: AI), Ascendis Pharma A/S (NASDAQ: ASND), Alvotech SA (NASDAQ: ALVO), and Shift4 Payments, Inc. (NYSE:...

Jun 17, 2023 05:30 pm ET

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma A/S (Nasdaq: ASND) today reported one-year (Week 52) data from its ongoing Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism. The data showed that treatment with TransCon PTH resulted in sustained improvements...

Jun 13, 2023 07:00 am ET

Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma A/S (Nasdaq: ASND) today announced it will showcase its latest Endocrinology Rare Disease programs, data, and research in growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome at ENDO 2023, the annual...

Jun 07, 2023 08:30 am ET

Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Jun 05, 2023 05:30 pm ET

Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany

Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has started enrollment for a Compassionate Use Program (CUP) in Germany for TransCon PTH (palopegteriparatide), an investigational prodrug designed to provide sustained release of active...

May 31, 2023 08:30 am ET

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Ascendis Pharma A/S (Nasdaq: ASND) will today host an investor meeting highlighting the latest developments in the Company’s Oncology programs, including clinical data updates and a review of clinical development strategy for the Company’s two...

May 25, 2023 08:30 am ET

Ascendis Pharma to Host Oncology Program Update on May 31

Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will host an Oncology program update for the investment community on Wednesday, May 31, 2023 in New York from 10:00 a.m. to 12:00 p.m. Eastern Time. The event will feature...

May 13, 2023 07:00 pm ET

Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023

Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will present clinical and research outcomes in hypoparathyroidism and growth hormone deficiency, and host informational booth and events, at ECE 2023, the European Congress of...

May 03, 2023 04:15 pm ET

Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference

May 01, 2023 09:58 am ET

Thinking about buying stock in Ascendis Pharma, IVERIC bio, Cardlytics, SoFi Technologies, or Elevation Oncology?

NEW YORK, May 1, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASND, ISEE, CDLX, SOFI, and ELEV.

May 01, 2023 07:00 am ET

U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has issued a complete response letter (CRL) for the TransCon PTH (palopegteriparatide) New Drug Application (NDA) for the treatment of adults with...

Apr 28, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ: FOX, FOXA), Ascendis Pharma A/S (NASDAQ: ASND), and Shift4 Payments, Inc. (NYSE: FOUR). Our...

Apr 27, 2023 04:01 pm ET

Ascendis Pharma Reports First Quarter 2023 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2023 and provided a business update. “Based on our clinical experience with TransCon PTH to date, we have seen the improvement in the...

Apr 24, 2023 01:33 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ascendis Pharma A/S - ASND

Pomerantz LLP is investigating claims on behalf of investors of Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQ: ASND). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....

Apr 22, 2023 07:00 am ET

ASCENDIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ascendis To Contact Him Directly To Discuss Their Options

NEW YORK, April 22, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ascendis Pharma ("Ascendis" or the "Company") (NASDAQ: ASND).

Apr 19, 2023 06:08 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ascendis Pharma A/S - ASND

NEW YORK, April 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ascendis Pharma A/S ("Ascendis" or the "Company") (NASDAQ: ASND). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Apr 17, 2023 05:57 pm ET

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Ascendis Pharma (NASDAQ: ASND) resulting from allegations that Ascendis may have issued materially misleading...

Apr 16, 2023 11:00 am ET

ROSEN, A TOP RANKED LAW FIRM, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND

NEW YORK, April 16, 2023 /PRNewswire/ --

Apr 13, 2023 08:30 am ET

Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold a conference call and live webcast on Thursday, April 27, 2023, at 4:30 p.m. Eastern Time (ET) to review its first quarter 2023 financial results and provide a business...

Apr 10, 2023 10:24 pm ET

ASND EQUITY NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND

NEW YORK, April 10, 2023 /PRNewswire/ --

Apr 08, 2023 07:00 am ET

ASCENDIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ascendis To Contact Him Directly To Discuss Their Options

NEW YORK, April 8, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ascendis Pharma ("Ascendis" or the "Company") (NASDAQ: ASND).

Apr 07, 2023 09:00 pm ET

ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQ: ASND) on behalf of Ascendis stockholders. Our investigation concerns whether Ascendis has violated the federal securities laws and/or engaged in other unlawful business practices.

Apr 04, 2023 05:52 pm ET

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQ: ASND). Investors who purchased Ascendis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/

Apr 04, 2023 04:59 pm ET

Ascendis Pharma A/S: Company Investigated by the Portnoy Law Firm

The Portnoy Law Firm advises Ascendis Pharma A/S (“Ascendis” or “the Company”) (NASDAQ: ASND) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Ascendis...

Apr 04, 2023 10:00 am ET

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ascendis Pharma A/S (“Ascendis” or “the Company”) (NASDAQ:

Apr 03, 2023 02:52 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm

Apr 03, 2023 10:51 am ET

ASND LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND

Apr 03, 2023 07:05 am ET

Ascendis Pharma’s Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon™ IL-2 β/γ Accepted for Online Publication at ASCO 2023

Ascendis Pharma A/S (Nasdaq: ASND) today announced that initial dose escalation data from the Company’s ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β/γ alone or in combination with pembrolizumab has been accepted for online publication at...

Apr 03, 2023 07:00 am ET

Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH™ in Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company’s New Drug Application (NDA) for...

Mar 10, 2023 08:00 am ET

Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Feb 16, 2023 04:01 pm ET

Ascendis Pharma Reports Full Year 2022 Results

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the full year ended December 31, 2022 and provided a business update. “Our unique TransCon technology platform and algorithm for product innovation enables us to address...

Feb 07, 2023 08:00 am ET

Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold a conference call and live webcast on Thursday, February 16, 2023, at 4:30 p.m. Eastern Time (ET) to review its 2022 financial results and provide a business update....

Jan 08, 2023 05:00 pm ET

Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on its Vision 3x3 strategic roadmap and planned 2023 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 9, at the 41st Annual J.P....

Jan 04, 2023 08:00 am ET

Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the online portal is now open for physicians wanting to request access to TransCon PTH (palopegteriparatide), the Company’s investigational parathyroid hormone replacement therapy, through the...

Jan 03, 2023 08:00 am ET

Ascendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND) announced today that the Company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference. Details: Event41st Annual J.P. Morgan Healthcare ConferenceLocationSan Francisco, CADateMonday,...

Dec 05, 2022 08:00 am ET

Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has allowed the Company to initiate an expanded access program (EAP) for its investigational parathyroid hormone replacement therapy, TransCon PTH...

Nov 22, 2022 08:30 am ET

Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in the 5th Annual Evercore ISI HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore. Details:...

Nov 14, 2022 07:00 am ET

Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism. TransCon PTH is...

Nov 13, 2022 06:15 pm ET

Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

TransCon CNP was generally well tolerated with low frequency of injection site reactions; all 57 randomized children continued, with the longest treatment duration beyond two years - Data showed robust and consistent results in prespecified...

Nov 11, 2022 12:10 pm ET

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Ascendis Pharma A/S (Nasdaq: ASND) today disclosed new data from the dose-escalation portion of transcendIT-101, the company’s Phase 1/2 open-label, multi-center trial of TransCon TLR7/8 Agonist in patients with advanced solid tumors. TransCon...

Nov 02, 2022 04:01 pm ET

Ascendis Pharma Reports Third Quarter 2022 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended September 30, 2022 and provided a business update. “With our improved commercial execution and emphasis on SKYTROFA’s unique patient-focused...

Oct 31, 2022 08:00 am ET

FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism and...

Oct 26, 2022 08:00 am ET

Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update Conference Call on November 2

Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, November 2, 2022, at 4:30 p.m. Eastern Time (ET) to review its third quarter 2022 financial results and provide a...

Oct 03, 2022 08:00 am ET

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid Tumors

Ascendis Pharma A/S (Nasdaq: ASND) today announced completion of the dose-escalation portion and recommendation of the Phase 2 dose in transcendIT-101, a Phase 1/2 clinical trial to evaluate the safety and efficacy of TransCon TLR7/8 Agonist in...

Sep 12, 2022 08:00 am ET

New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Pharma’s TransCon™ PTH through Week 110 in the PaTH Forward Trial Presented at ASBMR 2022

Ascendis Pharma A/S (Nasdaq: ASND) today announced new Week 110 data from the Phase 2 PaTH Forward Trial showing that long-term therapy with TransCon PTH, an investigational prodrug designed to provide sustained release of active parathyroid...

Sep 01, 2022 08:00 am ET

Ascendis Pharma A/S Announces Upcoming Investor Presentations in September

Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in three upcoming investor conferences in September. Details: EventCiti's 17th Annual BioPharma ConferenceLocationBoston, MADateWednesday, September...

Aug 31, 2022 08:27 am ET

Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational prodrug designed to restore parathyroid hormone (PTH [1-34]) to...

Aug 10, 2022 04:01 pm ET

Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2022, and provided a business update. “Our anticipated launch of TransCon PTH in the U.S. next year, combined with our progress towards...

Aug 04, 2022 08:00 am ET

Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10

Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, August 10, 2022, at 4:30 p.m. Eastern Time (ET) to review its second quarter 2022 financial results and provide a...

Jun 07, 2022 08:00 am ET

Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon™ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022

Ascendis Pharma A/S (Nasdaq: ASND) today announced that its presentations at ENDO 2022 will include oral presentations of Phase 2 and Phase 3 data for its investigational product candidate TransCon PTH in adult hypoparathyroidism (HP). During the...

May 23, 2022 08:00 am ET

Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments

Ascendis Pharma A/S (Nasdaq: ASND) today announced new Endocrinology commercial leadership appointments following the retirement of Global Chief Commercial Officer Jesper Høiland: Having established U.S. commercial operations, Jesper Høiland will...

May 23, 2022 08:00 am ET

Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial

Ascendis Pharma A/S (Nasdaq: ASND) announced today that results from VISEN Pharmaceuticals’ Phase 3 trial of once-weekly TransCon hGH in children with GHD in China demonstrated results that were consistent with the Ascendis Pharma’s earlier...

May 11, 2022 04:01 pm ET

Ascendis Pharma A/S Reports First Quarter 2022 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2022 and provided a business update. “This continues to be a transformative time for Ascendis as we build on positive Phase 3 data for...

May 09, 2022 08:00 am ET

Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to attend the BofA Securities 2022 Healthcare Conference. Company executives will participate in a fireside chat hosted by BofA on Thursday, May 12. Details EventBofA...

May 04, 2022 04:05 pm ET

Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update Conference Call on May 11

Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, May 11, 2022 at 4:30 p.m. Eastern Time (ET) to review its first quarter 2022 financial results and provide a business...

May 01, 2022 07:00 am ET

Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will present clinical and research outcomes and host informational booths and events at four medical meetings during May. Topics will include new open-label extension data for...

Mar 24, 2022 10:41 pm ET

Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced the pricing of its offering of US$500,000,000...

Mar 23, 2022 04:01 pm ET

Ascendis Pharma Announces Proposed Convertible Senior Notes Offering

Mar 13, 2022 05:53 pm ET

Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value 600 mg/day of calcium supplements) with no increase in prescribed study drug within the 4 weeks prior to the Week 26...

Mar 02, 2022 04:01 pm ET

Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the full year ended December 31, 2021 and provided a business update. “2021 was an extraordinary year for Ascendis, and we expect that 2022 will be even stronger. The...

Feb 25, 2022 08:00 am ET

Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at 4:30 p.m. Eastern Time (ET) to review its 2021 financial results and provide a business update....

Feb 10, 2022 04:05 pm ET

Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the 11th Annual SVB Leerink Global Healthcare Conference. Company executives will participate in a virtual fireside chat hosted by SVB Leerink....

Jan 13, 2022 08:00 am ET

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for Lonapegsomatropin Ascendis Pharma (developed under the name TransCon hGH) as a once-weekly subcutaneous injection for the...

Jan 10, 2022 08:00 am ET

Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will today provide an update on its Vision 3x3 and planned 2022 key milestones at the 40th Annual J.P. Morgan Healthcare Conference. Details of the update are outlined below, and...

Jan 04, 2022 08:00 am ET

Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Company executives will provide a business overview and update on the company’s pipeline...

Dec 14, 2021 08:00 am ET

Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across R&D Pipeline

Ascendis Pharma A/S (Nasdaq: ASND) today plans to provide an update on two of its investigational endocrinology rare disease development programs, TransCon PTH for hypoparathyroidism, and TransCon CNP for achondroplasia, and on one of its...

Dec 07, 2021 05:41 pm ET

Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tuesday, December 14, 2021. The event will feature updates on Ascendis Pharma’s endocrinology rare disease...

Nov 18, 2021 04:42 pm ET

Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparat

Ascendis Pharma A/S (Nasdaq: ASND), today announced top-line results from Week 84 of the Company’s Phase 2 PaTH Forward Trial, a global trial evaluating the safety, tolerability, and efficacy of its investigational TransCon PTH product candidate in...

Nov 17, 2021 04:05 pm ET

Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore ISI. Details...

Nov 15, 2021 08:00 am ET

Ascendis Pharma A/S - Share Repurchase Program Update

Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on the Company’s previously announced $25 million American Depositary Shares (ADS) Share Repurchase Program. Each ADS represents one ordinary share of Ascendis Pharma A/S. The program was...

Nov 12, 2021 07:22 am ET

Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization for Lonapegsomatropin...

Nov 10, 2021 04:01 pm ET

Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND), today announced financial results for the third quarter ended September 30, 2021. “We are at a defining moment on our way to fulfilling Vision 3x3, our strategy to build a leading global biopharma company. In...

Nov 09, 2021 08:00 am ET

Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon™ TLR7/8 Agonist Oncology Program at SITC 2021

Ascendis Pharma A/S (Nasdaq: ASND) today announced two poster presentations featuring new non-clinical data for its investigational TransCon™ TLR7/8 Agonist product candidate at SITC 2021, the annual meeting for the Society for Immunotherapy of...

Nov 08, 2021 08:00 am ET

Ascendis Pharma A/S - Share Repurchase Program Update

Nov 03, 2021 08:00 am ET

Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update Conference Call on November 10

Ascendis Pharma A/S (Nasdaq: ASND), today announced that the Company will hold a conference call and live webcast on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time (ET) to review its third quarter 2021 financial results and provide a...

Oct 15, 2021 08:00 am ET

Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have...

Sep 30, 2021 04:01 pm ET

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company using its innovative TransCon technologies to potentially create new treatments to make a meaningful difference in patients’ lives, today announced presentations featuring new data...

Sep 29, 2021 04:01 pm ET

Ascendis Pharma A/S Announces Share Repurchase Program

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, today announced that its Board of...

Sep 22, 2021 04:27 pm ET

Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company using its innovative TransCon™ technologies to potentially create new treatments to make a meaningful difference in patients’ lives, today announced 58-week BMD data from central lab...

Sep 07, 2021 05:09 pm ET

Ascendis Pharma A/S Announces Upcoming Investor Presentations

Sep 07, 2021 04:59 pm ET

Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program

Sep 01, 2021 07:43 pm ET

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Aug 31, 2021 04:01 pm ET

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Aug 25, 2021 04:12 pm ET

Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results

Aug 25, 2021 03:24 pm ET

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new treatments that make a meaningful difference in patients’ lives, today announced that the U.S. Food and...

Aug 17, 2021 04:17 pm ET

Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live...

Aug 06, 2021 07:05 am ET

Ascendis Pharma A/S Announces Upcoming Investor Presentations in August

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create new product candidates that address unmet medical needs, today announced that the company will participate in two upcoming...

Jul 06, 2021 08:00 am ET

Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global

Jun 11, 2021 05:57 pm ET

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency

May 28, 2021 07:05 am ET

Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021

May 27, 2021 04:01 pm ET

Ascendis Pharma A/S Reports First Quarter 2021 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced financial results for the first quarter ended March...

May 17, 2021 04:05 pm ET

Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27

May 12, 2021 04:28 pm ET

Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that it has filed a Clinical Trial Notification (CTN)...

May 10, 2021 05:17 pm ET

Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-To

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, today announced preliminary 58-week results from the continuing...

May 06, 2021 04:05 pm ET

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH at Upcoming Medical Conferences

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations featuring TransCon PTH at two upcoming medical conferences: the 48th...

May 04, 2021 04:05 pm ET

Ascendis Pharma A/S Announces Participation at the BofA Securities 2021 Virtual Health Care Conference

Apr 21, 2021 04:05 pm ET

Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences

Mar 30, 2021 07:05 am ET

Ascendis Pharma A/S Announces Participation at the J.P. Morgan 10th Annual Napa Valley Biotech Forum

Mar 23, 2021 07:05 am ET

Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today presented the safety and efficacy results of TransCon PTH after...

Mar 15, 2021 07:05 am ET

Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference

Mar 10, 2021 04:01 pm ET

Ascendis Pharma A/S Reports Full Year 2020 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced financial results for the full year ended December...

Mar 10, 2021 07:05 am ET

Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced seven presentations at ENDO 2021, the Endocrine Society’s annual meeting, taking...

Mar 04, 2021 04:05 pm ET

Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10

Feb 26, 2021 07:05 am ET

Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the launch of Outgrow GHD, a new online educational resource designed to help...

Feb 18, 2021 04:05 pm ET

Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference

Jan 10, 2021 07:04 pm ET

Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, will provide an update on Vision 3x3 and the company’s 2021 key...

Jan 08, 2021 09:06 pm ET

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

SHANGHAI, Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced today the closing of a $150 million Series B financing.

Jan 08, 2021 07:39 pm ET

Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals

Jan 04, 2021 07:05 am ET

Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference

Dec 30, 2020 04:05 pm ET

Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program

Dec 14, 2020 04:05 pm ET

Ascendis Pharma A/S Announces Planned Board Transition

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced a planned board transition at the 2021 Annual General...

Nov 25, 2020 07:05 am ET

Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

Nov 11, 2020 05:30 pm ET

Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20

Nov 11, 2020 04:01 pm ET

Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced financial results for the quarter ended September 30,...

Nov 03, 2020 07:05 am ET

Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that it has appointed Mark A. Bach, M.D., Ph.D., as Senior Vice President of...

Nov 02, 2020 04:05 pm ET

Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, November...

Oct 23, 2020 08:05 am ET

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the European Commission (EC) has granted Orphan Designation to TransCon PTH for the...

Oct 21, 2020 05:50 pm ET

Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced five presentations featuring the company’s endocrinology rare disease programs at...

Sep 28, 2020 07:00 pm ET

Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon PTH in Adult Hypo

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced preliminary six-month results from the open-label extension (OLE) portion of PaTH...

Sep 23, 2020 04:05 pm ET

Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in Japan

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it has filed a Clinical Trial Notification (CTN) with the Pharmaceuticals and...

Sep 15, 2020 05:45 pm ET

Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2020

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative technologies to address unmet medical needs, today announced its support of Children’s Growth Awareness Week, taking place September 13–19, 2020, and...

Sep 11, 2020 07:05 am ET

Ascendis Pharma A/S Announces Participation at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in the 18th Annual Morgan Stanley Virtual Global...

Sep 10, 2020 07:05 am ET

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual Meeting

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced three presentations for its TransCon PTH program for hypoparathyroidism (HP) at the...

Sep 08, 2020 04:44 pm ET

Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that uses its novel TransCon technologies to address unmet medical needs, announced today the submission of a MAA to the EMA seeking approval for TransCon hGH (lonapegsomatropin), an...

Sep 04, 2020 08:30 am ET

Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that uses its novel TransCon technologies to address unmet medical needs, today announced that the FDA has accepted the company’s BLA for TransCon hGH (lonapegsomatropin), an...

Sep 04, 2020 07:05 am ET

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at 22nd European Congress of Endocrinology

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced two presentations for its TransCon PTH program in adult hypoparathyroidism (HP) at...

Sep 02, 2020 04:05 pm ET

Ascendis Pharma A/S Announces Participation at the 2020 Wells Fargo Virtual Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in the 2020 Wells Fargo Virtual Healthcare...

Aug 27, 2020 04:01 pm ET

Ascendis Pharma A/S Reports Second Quarter 2020 Financial Results and Announces New Data from the Four-Week, Fixed Dose, Double-Blind Portion of the PaTH Forward Trial

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced new data from PaTH Forward and financial results for the quarter ended June 30, 2020....

Aug 13, 2020 04:01 pm ET

Ascendis Pharma A/S Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 27

Aug 12, 2020 07:05 am ET

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe

Aug 04, 2020 08:30 am ET

Ascendis Pharma A/S Announces Upcoming Investor Presentations in August

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in two upcoming investor conferences in August....

Jul 07, 2020 10:11 pm ET

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced the pricing of its underwritten public offering of 4,225,352 American Depositary...

Jul 06, 2020 12:58 pm ET

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that it has commenced an underwritten public offering of $500,000,000 of American...

Jul 06, 2020 09:25 am ET

Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it received a positive opinion from the Paediatric Committee (PDCO) of the...

Jun 26, 2020 08:29 am ET

Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...

Jun 22, 2020 08:30 am ET

Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the presentation of preclinical data for TransCon IL-2 β/γ, an oncology product...

Jun 08, 2020 08:15 am ET

Ascendis Pharma A/S Announces Participation in ENDO Online 2020

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations related to its rare disease endocrinology programs at ENDO Online 2020,...

May 19, 2020 04:01 pm ET

Ascendis Pharma A/S Reports First Quarter 2020 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced financial results for the quarter ended March 31, 2020. “We continue to execute on...

May 11, 2020 08:30 am ET

Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will appoint Jesper Høiland as Global Chief Commercial Officer upon...

May 07, 2020 04:01 pm ET

Ascendis Pharma A/S Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 19

Apr 19, 2020 04:00 pm ET

Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced positive top-line results from the four-week fixed dose, blinded portion of PaTH...

Apr 15, 2020 04:58 pm ET

Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Orphan...

Apr 01, 2020 04:01 pm ET

Ascendis Pharma A/S Reports Full-Year 2019 Financial Results

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced financial results for the full year ended December 31, 2019. “Following a...

Mar 25, 2020 04:01 pm ET

Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1

Feb 12, 2020 04:01 pm ET

Ascendis Pharma A/S Announces Upcoming Investor Presentation in February

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in the upcoming SVB Leerink 9th Annual Global...

Jan 12, 2020 07:45 pm ET

Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, will provide an outlook for 2020 and review progress towards Vision 3x3, the company’s...

Jan 09, 2020 04:00 pm ET

Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in the upcoming 38th Annual J.P. Morgan Healthcare...

Nov 18, 2019 04:01 pm ET

Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results

Nov 14, 2019 04:01 pm ET

Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address unmet medical needs, today announced a protocol addendum designed to facilitate enrollment of subjects previously treated...

Nov 08, 2019 04:02 pm ET

Ascendis Pharma A/S Announces Upcoming Investor Presentation in November

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in the Stifel 2019 Healthcare Conference in...

Nov 06, 2019 04:02 pm ET

Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019

Nov 04, 2019 06:30 pm ET

Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18

Oct 21, 2019 04:04 pm ET

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

Sep 26, 2019 08:25 am ET

Ascendis Pharma A/S Announces Upcoming Investor Presentation in October

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate at the 2019 Cantor Global Healthcare Conference in...

Sep 12, 2019 04:20 pm ET

Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced four presentations on achondroplasia and TransCon CNP, the company’s investigational...

Aug 29, 2019 05:15 pm ET

Ascendis Pharma A/S Announces Three Investor Presentations in September

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in three upcoming investor conferences in...

Aug 28, 2019 04:01 pm ET

Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results

Aug 14, 2019 05:30 pm ET

Ascendis Pharma A/S Announces Second Quarter 2019 Financial Results and Business Update Conference Call on August 28

Jul 29, 2019 08:00 am ET

Ascendis Pharma A/S Announces Participation in August Investor Conferences

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in two upcoming investor conferences in August....

Jul 18, 2019 04:12 pm ET

Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address significant unmet medical needs, today announced the filing of an investigational new drug (IND) application with the U.S....

Jun 19, 2019 08:30 am ET

Ascendis Pharma A/S Announces R&D Day on June 26 to Review Endocrinology Rare Disease Pipeline and Introduce Oncology Programs

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the company will host an R&D Day for the investment community on Wednesday, June...

Ad blocking detected

Ascendis Pharma A/S (ADR) (OQ:ASND)

Business Focus: Bio Therapeutic Drugs